Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120691 · ClinicalTrials.gov registry record · Phase 3
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,224
- Enrollment target
NCT01120691: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01120691 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,224 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (188% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120691, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,224 participants
- Enrollment target
Study Summary
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
Primary Outcome
A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of modera
Interventions
- DRUG tiotropium
- DRUG NVA237
- DRUG QVA149
- DRUG Salbutamol/albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,224 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
What the finished NCT01120691 record still lists
NCT01120691 is an interventional study that assigns participants to a tested intervention. Its 2,224 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (188% higher).
The record links to 0 conditions, and to 4 interventions - of which tiotropium is the first listed.
NCT01120691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01120691 about?
NCT01120691 is a clinical study titled "Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations". This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
What is the current status of trial NCT01120691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,224 participants. The study started on 2010-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01120691?
The interventions under investigation include: tiotropium (DRUG), NVA237 (DRUG), QVA149 (DRUG), Salbutamol/albuterol (DRUG).
Who is sponsoring clinical trial NCT01120691?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01120691's enrollment target sits among peer trials
2,224 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia